𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: Novocure today announced positive overall survival data for its tumor treating fields technology in hard to treat pancreatic cancer. #ASCO25 $NVCR Full video: biotechtv.com/post/novocure-…

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: Arvinas's CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation. #ASCO25 $ARVN Full video: biotechtv.com/post/arvinas-a…

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: Arcus Biosciences's CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer. #ASCO25 $RCUS Full video: biotechtv.com/post/arcus-bio…

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at #ASCO25 as well as early stage data for emerging CAR-T targets against solid tumors. $LEGN Full video: biotechtv.com/post/legend-bi…

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: Bicara Therapeutics's CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor. #ASCO25 $BCAX Full video: biotechtv.com/post/bicara-th…

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: Protagonist Therapeutics's CEO Dinesh Patel discusses the results of the phase 3 study of Rusfertide for polycythemia vera, plus a recap of recent ulcerative colitis data for its IL-23R. #ASCO25 $PTGX Full video: biotechtv.com/post/protogoni…

𝐁𝐫𝐢𝐠𝐡𝐭𝐬 𝐌𝐢𝐧𝐝𝐬: Deerfield Managing Partner James Flynn discusses a new $600M venture fund the firm has raised and describes how it will be invested, including into AI companies. Full video: biotechtv.com/post/deerfield…

𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬: Breakout Ventures's lindy fishburne on transitioning from the philanthropic Breakout Labs within the Thiel Foundation to Breakout Ventures, a traditional venture firm that has a diverse set of limited partners. Full video: biotechtv.com/post/bioventur…

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: The leaders of Daiichi Sankyo US discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging. Full video: biotechtv.com/post/daiichi-s…

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: Allogene Therapeutics presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate. #ASCO25 $ALLO Full video: biotechtv.com/post/allogene-…

𝐊𝐥𝐞𝐢𝐧 𝐇𝐞𝐫𝐬𝐡 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐄𝐱𝐞𝐜𝐮𝐭𝐢𝐯𝐞 𝐒𝐞𝐚𝐫𝐜𝐡: Klein Hersh's Lonnie Brantz, Zach Spitz, and Jeffrey Azarva discuss oncology trends, the evolving talent landscape, and building long-term relationships at #ASCO25. kleinhersh.com #sponsored

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: Strand Therapeutics's Co-Founder & CEO Jake Becraft discusses the clinical data presentation for the company's IL-12, self-replicating mRNA cancer immunotherapy. #ASCO25 Full video: biotechtv.com/post/strand-th…

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: Candel Therapeutics's CEO Dr. Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy. #ASCO25 $CADL Full video: biotechtv.com/post/candel-th…

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer. #ASCO25 Full video: biotechtv.com/post/transgene…

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: PharmaMar presented data showing that the combo of Zepzelca and Tecentriq significantly improved survival as first-line maintenance therapy for extensive-stage small cell lung cancer. #ASCO25 Full video: biotechtv.com/post/pharmamar…

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Kymera Therapeutics Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company's STAT6 healthy volunteer data. $KYMR Full video: biotechtv.com/post/kymera-th…

𝐀𝐈 𝐍𝐞𝐰𝐬: FDA launched Elsa, a generative AI tool designed to streamline drug and device reviews. With staff cuts and tighter budgets, will AI keep review timelines on track?

𝐀𝐈 𝐍𝐞𝐰𝐬: Can AI really match classic expert systems in clinical diagnosis? A new study finds both have strengths, and suggests a hybrid approach could help catch diagnoses that might otherwise be missed. Here’s what that could mean for clinicians.

𝐀𝐈 𝐍𝐞𝐰𝐬: ArteraAI presented data at #ASCO25 showing that its AI platform can identify prostate cancer patients most likely to benefit (or not benefit) from added androgen receptor inhibitor therapy. Full video: biotechtv.com/post/artera-as…

𝐍𝐮𝐜𝐥𝐞𝐚𝐭𝐞: Nucleate's Nucleate UK chapter held its "The Forum" event in London - where it brought together the biotech community for networking, education, and to celebrate companies that have been through its Activator program. Link: biotechtv.com/post/nucleate-…